With four orders with a total value of 7.5 MSEK in the last eight months, of which two booked in the first two months of 2022, it is now clear that fucoxanthin offers the most significant commercial potential for Simris and that B2B is the most lucrative way forward. While this warrants an upward adjustment of our somewhat dated sales forecast (from 12 to 15 MSEK in 2022), Simris ability to leverage its unique algae platform will also depend on its access to growth capital.
Orders year to date amounting to half of sales in 2021
The two fucoxanthin orders in Q1’22 with a total value of 3 MSEK, corresponds to roughly half of the company’s total sales in 2021 at 6.1 MSEK, of which 4.5 MSEK also was fucoxanthin. This clearly illustrates not only that this has now become Simris’ by far most lucrative business, it also shows that the B2B-segment is the right strategic path for Simris and that the company is now on track to capitalise on the growing demand from the nutritional, cosmeceutical and pharma industries.
As for the omega-3 vertical, Simris has decided to withdraw its EFSA Novel Food application, partly because Simris will most likely use a higher yielding stem for its omega-3 product, but also because of Simris’ change in business focus to the considerably more valuable fucoxantin.
International micro algae space gaining momentum
In a global perspective, the micro algae industry has attracted considerable VC financing in the past five years, which along with the M&A-activity ranges into several hundreds of million USD. At the same time, the whole microalgae market can still be considered to be in its infancy, as various market research firms estimate the total global market (excluding biofuels) to be less than
In terms of peers,
Time to capitalise on unique micro algae platform
We have long argued that Simris has a unique micro algae platform that offers considerable opportunities in an international perspective and that the announcement of new B2B deals is the key to unlocking this potential. Unfortunately, the share still suffers from a crisis of confidence stemming from previous management and an historic overemphasis on the short-term sales development of the omega-3 product line. With sales in 2021 at 6.1 MSEK, Simris managed to surpass our previous sales expectation at 4 MSEK. With the orders to date we have updated our revenue expectations for 2022 from 12 MSEK to 15 MSEK, which also includes our lowered expectations for the omega-3. Chairman
While the two fucoxanthin orders to date will be delivered from existing inventory, the liquidity situation can be described as tight, with cash at
So all in all, we continue to see a significant revaluation potential in Simris, and that the triggers are now starting to line up.
We apply a 6x sales multiple to our forecast for 2023 (derived from a third of the sales multipe of
Read here https://www.emergers.se/simris_i/
© Modular Finance, source